Skip to main content
. 2021 Sep 8;13(9):1793. doi: 10.3390/v13091793

Figure 4.

Figure 4

Time-of-Drug-Addition Analysis of PFME against EBOVpp Infection. (A) Schematic of time-of-drug-addition analysis of PFME (30 μg/mL) treatment against EBOVpp (MOI 0.01) infection on Huh-7 cells using (B) pretreatment and (C) co-addition models. For the co-addition assay, EBOV GP-neutralizing antibody KZ52 [31] was included as a positive control. For both experiments, DMSO (0.01%) treatment served as negative control. Luciferase reporter assay was performed at 72 h post-infection to assess EBOVpp infection. Data are expressed as mean RLU ± SD from three independent experiments. Asterisks (*) denote statistical significance: **** p < 0.0001.